ALPMY News and Press, Astellas Pharma Inc. ADR From 10/30/20

Astellas Pharma ADR (ALPMY): 1H Non-GAAP EPS of ¥57.15; GAAP EPS of ¥39.19.Revenue of ¥615.48B (-5.4% Y/Y)Press Release For further details see: Astellas Pharma ADR reports 1H results

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...

Astellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging Agent PR Newswire TOKYO, Oct. 28, 2020 TOKYO , Oct. 28, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARD Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies PR Newswire TOKYO, Oct. 20, 2020 TOKYO , Oct. 20, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TS...

New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined 42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented PR Newswire TOKYO, Oct. 19, 2020 TOKYO ...

Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer - Durable Responses Observed in Patients Who Had Previously Received Immunotherapy but Were Ineli...

Virios Therapeutics has filed to raise $30 million in an IPO of its common stock. The firm is developing a proprietary formulation for the treatment of fibromyalgia, a pain condition. VIRI has achieved intriguing early efficacy results, received fast track review status and the IP...

Astellas and MBC BioLabs Announce Golden Ticket Competition to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators ...

Astellas' Real-World Evidence Studies Provide Further Insight into Negative Impacts of Vasomotor Symptoms (VMS) Associated with Menopause New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting PR Newswire TOKYO, Sept. 28, ...

TOKYO and BOTHELL, Wash. , Sept. 18, 2020 /PRNewswire/ --  Astellas Pharma Inc.  (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc . (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV ® (enfortumab vedotin-ejfv) met ...